What is a DoT? Do we like it a lot?

Nadine Hillock

National Antimicrobial Utilisation Surveillance Program





Acknowledgment of country


We acknowledge the Traditional Owners of the lands we are on today and pay our respects to their Elders, past, present and emerging. Overview: Surveillance of antimicrobial use & Days of Therapy (DoTs)

- > Purpose of surveillance of antimicrobial use
- > How are we currently quantitatively measuring usage in Australian hospitals?
- > Alternative metrics
- > The definition of a DoT
- > Challenges of using DoTs for surveillance



Why measure antimicrobial use?

- > If you cannot measure it, you cannot improve it
- Identify areas for more targeted interventions, or more detailed investigation of usage
 Figure 15: Third- and fourth-generation cephalosporin usage rates in NAUSP contributor hospitals, by independent of any 2014 (2019) (2019)
- > Trends over time
 - Before and after interventions
 - Impact of shortages
 - Not always about decreasing use




Source: Supplement: Biennial report of the NAUSP: 2017-2018

Why measure antimicrobial use?

> Benchmarking

- Between hospitals, between units, between countries
- Understanding change in comparison to others



Benchmarking internationally is limited to the countries using the same metric to quantify usage



Source: Supplement: Biennial report of the NAUSP: 2017-2018

Surveillance to inform AMS & research

- Surveillance can help us ask better questions target research
- > Quantitative surveillance complements and informs qualitative surveillance
- > Requires a standard unit of measure usually expressed as a rate (or usage density):


numerator	measure of antimicrobial use		
denominator	\rightarrow	number of opportunities for antimicrobial use	



How do we currently quantify usage in hospitals?

- > Volume-based surveillance, population data
- > Antimicrobial usage rate = DDDs per 1,000 occupied bed days (OBDs)
 - Defined Daily Dose (DDD) specified by WHO ATC

https://www.whocc.no/atc_ddd_index/



- DDD = "the assumed average maintenance dose per day for a drug used for its main indication in adults"
- Surveillance definition: not intended to guide clinical dosing

What alternative metrics can be used?

- > Many alternatives what is optimal?
- > Better information leads to better outcomes
- > Systematic review to identify the "best" surveillance method


J Antimicrob Chemother 2018; **73** Suppl 6: vi50–vi58 doi:10.1093/jac/dky118 Journal of Antimicrobial Chemotherapy

Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure

Mirjana Stanić Benić ()^{1,2*}, Romina Milanič², Annelie A. Monnier ()^{3–5}, Inge C. Gyssens^{3,5}, Niels Adriaenssens^{6,7}, Ann Versporten⁶, Veronica Zanichelli⁸, Marion Le Maréchal⁹, Benedikt Huttner ()^{8,10}, Gianpiero Tebano⁹, Marlies E. Hulscher⁴, Céline Pulcini^{9,11}, Jeroen Schouten⁴ and Vera Vlahović-Palčevski^{1,2} on behalf of the DRIVE-AB WP1 group†

What alternative metrics can be used?

> Conclusion of the authors: "Antibiotic use should be preferable expressed in at least two metrics simultaneously"





What is a DoT?

- > Definition of a Days of Therapy (DoTs)
 - 'the aggregate sum of days for which any amount of a <u>specific</u> antimicrobial agent was administered to an individual patient as documented in the eMAR'

- > Also known as 'Antimicrobial days'
- > Advantages:
 - Inclusive of paediatrics
 - Can benchmark against other countries where DoTs are commonly used



Other numerators

- > LoT = Length of therapy
 - > 'Duration of antimicrobial exposure irrespective of the number of antimicrobials administered each day'
- More useful for patient-level monitoring than hospital level, e.g. by indication
- > Can be used as a ratio with DoTs to provide an aggregate measure for combination therapy (DoT/LoT ratio)



Advantages / Disadvantages of various numerators

	DDDs	DoTs	LoTs
Benefits	 Easily calculated Does not require patient- level data Can be used for cost calculations (because grams are measured) Accounts for combination therapy 	 Can be used for surveillance & benchmarking of paediatric usage Not affected by dose 	 Useful to monitor and inform AMS in specific specialty areas, or by indication
Limitations	 Adults usage only Doesn't account for patients with altered pharmacokinetics Over- or under-estimates where WHO reference DDD differs from administered dose 	 Only days of administration counted (doesn't count if dosing interval >24hours) Doesn't measure dose Each drug is counted separately so a patient on combination therapy has double the DoTs compared to a patient on monotherapy 	 Patient-level data required for calculation Not drug specific

Denominators

- > Occupied Bed Days (OBDs) bed occupancy at midnight
 - Limitations: allows surveillance of inpatient usage only
 - No way of measuring usage in locations/specialties where no overnight stay
- > Alternative denominators:
 - Theatre cases
 - ED presentations
 - Patient Days (PDs) 'total number of days for all patients admitted for an episode of care and who separated during a specified reference period. A patient admitted and separated on the same day is allocated 1 PD' (AIHW)
 - Easily accessible administrative data
 - Separations
 - Admissions



DoTs - definition and limitations

- > Count DoTs by drug, or count DoTs by drug by route of administration?
- > Illustrated by IV to oral switch
- > Example 1: Same drug, different route
 - Flucloxacillin 1g IV 8am, then flucloxacillin 500mg po qid from 2pm for 5 days

	LoTs (cumulative)	DoTs (fluclox total)	DoTs (fluclox by route)
Day 1	1	1	2
Day 2	2	1	1
Day 3	3	1	1
Day 4	4	1	1
Day 5	5	1	1
Total	5	5	6

DoTs - definition and limitations

- > Example 2: Combination therapy
 - E.g. Patient X on benzylpenicillin 1.2g IV every 6 hours for 5 days, and doxycycline 100mg orally twice daily for 5 days

	LoTs	DoTs
Day 1	1	2
Day 2	2	2
Day 3	3	2
Day 4	4	2
Day 5	5	2
Total	5	10



DoTs - definition and limitations

Example 3: Patient Y on gentamicin 80mg every 48 hours for 5 days

	LoTs	DoTs
Day 1	1	1
Day 2	2	0
Day 3	3	1
Day 4	4	0
Day 5	5	1
Total	5	3

> DoT surveillance only counts the **days of administration**



Sources of the data

- > Pharmacy dispensing / distribution data
 - Current data source for DDDs
 - Not actual administration data
 - Supply ≠ consumption

> EMR – antimicrobial ordered (not administered)

> eMAR – antimicrobial administered DoT data extraction



Extracting data from EMR/eMAR

- > Capability of NAUSP contributors proportion with eMAR / EMR systems
- > 231 hospitals currently / previously contributing data to NAUSP:
 - 119 (52%) have indicated some EMR / eMAR capacity
 - 66 have EMR with integrated eMAR
 - 13 EMR with separate eMAR
 - 23 eMAR with no EMR
 - 17 EMR with no eMAR

102 (44%) have some eMAR capability



Extracting DoT data from eMAR

- > Data fields required to extract DoTs at a patient level:
 - Patient identifier (name/MRN)
 - Date & time of administration of antimicrobial
 - Specialty of prescribing team
 - Antimicrobial name
 - Antimicrobial route of administration
- > One data row represents one antimicrobial administered by patient by specialty, by route of administration

Hospital-level DoT data for National surveillance

- > No patient identifiers
- Monthly aggregate of DoTs per antimicrobial, stratified by route of administration and specialty

AntimicrobialOrderedmapped	DateAdministered	DoseAdministered	UOMAdministered	RouteAdministered	DOTs	MappedSpecialty	Paediatric / Adult
flucloxacillin	08/01/2020 19:30	1000	mg	oral	1	Emergency	Adult
hydroxychloroquine	20/01/2020 11:14	200	mg	oral	1	Emergency	Adult
cefTRIAXONE	15/01/2020 07:43	1	g	intraVENOUS	1	Palliative care	Paediatric
doxycycline	05/01/2020 06:10	200	mg	oral	1	Emergency	Paediatric
cefTRIAXONE	05/01/2020 05:10	2	g	intraVENOUS	1	Emergency	Adult

- > Can be aggregated by specialty when extracted from eMAR or can be summed by NAUSP portal
- > Paediatric or adult use


Challenges of extracting data from eMAR or EMR

- Some sites have more that one eMAR system, e.g. different system in either ED or ICU
- > Extraction time / formatting may be long for larger sites (large data set)
- > Patient identifiers need to be removed before data can be added into a national surveillance dataset
- > Continuous infusions variable methods of documentation in eMAR




Challenges of collecting DoTs for national surveillance

- > Many different EMR/eMAR systems across Australia direct interface between the NAUSP portal & individual systems very resource intensive
- Monthly eMAR data extracts uploaded manually to the portal from each hospital




A DoT on a plot – is it hot, is it not?

- > Surveillance data is not useful if we cannot interpret it
- > Presentation of surveillance data needs to be easy to understand, clinically relevant, timely
- > Audience-specific, e.g. clinicians/prescribers, managers/policymakers



Source: Graber, CJ., et al. CID 2020; 71(5): 1168-76

A DoT on a plot – is it hot, is it not?



Source: Graber, CJ., et al. CID 2020; 71(5): 1168-76

Benchmarking

- Inconsistent metrics used globally to quantify hospital usage
 - European countries favour DDDs as a numerator for comparative rates (and to measure total prescription volume)
 - USA DOTs/ Days present (Patient days)
 - Japan DDDs/1,000 inhabitants/day



The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group

Daisuke Yamasaki,¹ Masaki Tanabe,^{⊠1} Yuichi Muraki,² Genta Kato,³ Norio Ohmagari,⁴ and Tetsuya Yagi⁵

European Surveillance of Antimicrobial Consumption Network (ESAC-Net)

Networks and partnerships

🎔 f in 🖂

About the network 🕨

ESAC-Net (formerly ESAC) is a Europe-wide network of national surveillance systems, providing European reference data on antimicrobial consumption. Data collection and analysis ►

The network continues collecting reference data on the consumption of antimicrobials for systemic use in the community and in the hospital sector in EU and EEA/EFTA countries through the European Surveillance System (TESSy).



Conclusion: A DoT on a plot – do we like it a lot?

- > No specific numerator or denominator is perfect – all have limitations
- > Two metrics are better than one
- DoTs per Patient Days will allow surveillance and benchmarking of paediatric hospitals
- Many challenges to overcome in getting standardised data from the various eMAR systems

So that is a DOT? Is it hot? Is it not? A DOT on a plot. Do we like it a lot? Will it help AMS? We will see, you and me. We will see what is best, the DOT or DDD

Acknowledgements

The National Antimicrobial Utilisation Surveillance Program is funded by the Australian Commission on Safety and Quality in Healthcare and SA Health

www.sahealth.sa.gov.au/nausp

Email: NAUSPhelp@sa.gov.au

@NAUSP_au



Government of South Australia

SA Health